Diagnosis and Treatment of Mechanical Hemolysis after Mitral Repair in Adult
Keywords:mitral repair, mitral regurgitation, mitral valve replacement, mechanical hemolytic anemia, multiple organ failure
Background: Mitral repair has been widely used in the treatment of secondary mitral lesions in recent years. Hemolytic anemia is known to be a rare complication after mitral repair. This study aimed to investigate the diagnosis and treatment of mechanical hemolysis after mitral repair in adults.
Methods: In this retrospective study, we reviewed the medical records of patients undergoing mitral repair complicated with mechanical hemolysis at our institution between August 2006 and May 2020.
Results: Twenty-four patients undergoing mitral repair complicated with mechanical hemolysis were included in the study. They were divided into two groups: the reoperation group (patients who underwent reoperation; N = 18) and the conservative treatment group (patients who received symptomatic treatments, including blood transfusion, diuresis, alkalization of urine, liver protection, hemodialysis, and oral metoprolol; N = 6. All patients in the reoperation group underwent mitral valve replacement. There were six hospital deaths, all in the conservative treatment group. Seventeen of eighteen patients (94.4%) completed follow up. Fifteen of seventeen survivors (88.2%) were in NYHA class I and 11.8% (2/17) in NYHA class II at the last time follow up.
Conclusions: Hemolysis is a sign of failure of mitral repair. Reoperation is the best choice once the hemolysis has been diagnosed. Reoperation should be carried out as soon as possible.
Abe T, Terada T, Noda R, et al. 2010. Annuloplasty ring removal from patients with hemolysis after mitral valve repair. J Card Surg. 25:683-5.
Aoyagi S, Fukunaga S, Tayama E, et al. 2007. Benefits of a β-blocker for intractable hemolysis due to para prosthetic leakage. Asian Cardiovasc Thorac Ann. 15:441-443.
Acharya D, McGiffin DC. 2013. Hemolysis after mitral valve repair. J Card Surg. 28:129-32.
Cerfolio RJ, Orszulak TA, Daly RC, et al. 1997. Reoperation for hemolytic, anaemia complicating mitral valve repair. Eur J Cardio-Thoracic Surg. 11:479-484.
Cerfolio RJ, Orzulak TA, Pluth JR, et al. 1996. Reoperation after valve repair for mitral regurgitation: early and intermediate results. J Thorac Cardiovasc Surg. 111:1177-83.
Chan CH, Pieper IL, Fleming S, et al. 2014. The effect to shear stress on the size, structure, and function of human von willebrand factor. Artif Organs. 38: 741-750.
Demirsoy E, Yilmaz O, Sirin G, et al. 2008. Hemolysis after mitral valve repair: a report of five cases and literature review. J Heart Valve Dis. 17:24-30.
Dilip KA, Vachaspathy P, Clarke B, et al. 1992. Haemolysis following mitral valve repair. J Cardiovasc Surg (Torino). 33:568-9.
Eishi K. 2001. Notes to avoid failure in mitral valvuloplasty. Ann Thorac Cardiovasc Surg. 7(2):69-74.
El Sabbagh A, Reddy YNV, Nishimura RA. 2018. Mitral Valve Regurgitation in the Contemporary Era: Insights Into Diagnosis, Management, and Future Directions. JACC Cardiovasc Imaging. 11:628-643.
Garcia MJ, Vandervoort P, Stewart WJ, et al. 1996. Mechanisms of hemolysis with mitral prosthetic regurgitation. Study using transesophageal echocardiography and fluid dynamic simulation. J Am Coll Cardiol. 27:399-406.
Ishibashi N, Kasegawa H, Koyanagi T, et al. 2005. Mechanism of hemolysis after mitral valve repair and new surgical management: prosthetic annuloplasty ring covered with autologous pericardium. J Heart Valve Dis. 14:588-91.
Ishida R, Adachi T, Shiotsu Y, et al. 2015. Reoperation after mitral valve repair in viewpoints of kidney injury as well as hemolytic anemia [published correction appears in CEN Case Rep. 2015 Nov;4(2):248]. CEN Case Rep. 4:119-125.
Lam BK, Cosgrove DM, Bhudia SK, et al. 2004. Hemolysis after mitral valve repair: mechanisms and treatment. Ann Thorac Surg. 77:191-5.
Lee IH, Kang GW, Kim CY, et al. 2020. Renal hemosiderosis secondary to intravascular hemolysis after mitral valve repair: A case report. Medicine (Baltimore). 99:e18798.
Matsunaga Y, Ishimura M, Nagata H, et al. 2018. Thrombotic microangiopathy in a very young infant with mitral valvuloplasty. Pediatr Neonatol. 59:595-599.
Naik AV, Bhalgat PS, Bhadane NS, et al. 2016. Very early onset traumatic hemolysis following mitral valve repair in a pediatric patient. Indian Heart J. 68 Suppl 2:S237-S240.
Nakaoka Y, Kubokawa SI, Yamashina S, et al. 2017. Late rupture of artificial neochordae associated with hemolytic anemia. J Cardiol Cases. 16:123-125.
Pollet C, Ravan R, Marcaggi X, et al. 2008. Hemolytic anemia following mitral valve surgery. Ann Cardiol Angeiol (Paris). 57:299-302.
Qian Q, Nath KA, Wu Y, Daoud TM, Sethi S. 2010. Hemolysis and acute kidney failure. Am J Kidney Dis. 56:780-784.
Rose JC, Hufnagel CA, Freis ED, et al. 1954. The hemodynamic alterations produced by a plastic valvular prosthesis for severe aortic insufficiency in man. J Clin Invest. 33:891-900.
Suri RM, Schaff HV, Dearani JA, et al. 2006. Recurrent mitral regurgitation after repair: should the mitral valve be rerepaired? J ThoracCardiovasc Surg. 132:1390-1397.
Tsang W. 2019. Recent advances in understanding and managing mitral valve disease. F1000Res. 8:F1000 Faculty Rev-1686.
Vahanian A, Alfieri O, Andreotti F, et al. 2012. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 33:2451-2496.
Vahidkhah K, Cordasco D, Abbasi M, et al. 2016. Flow-induced damage to blood cells in aortic valve stenosis. Ann Biomed Eng. 44:2724-2736.
Warnes C, Honey M, Brooks N, et al. 1980. Mechanical haemolytic anaemia after valve repair operations for non-rheumatic mitral regurgitation. Br Heart J. 44:381-385.
Weill O, Peyre M, Vergnat M, et al. 2015. Repeat mitral valve repair for haemolysis in children. Arch Cardiovasc Dis. 108:118-121.
Yeo TC, Freeman WK, Schaff HV, et al. 1998. Mechanisms of hemolysis after mitral valve repair: assessment by serial echocardiography. J Am Coll Cardiol. Sep;32:717-23.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).